[PL Developments Inc.], a leading manufacturer, packager and distributor of OTC products, has acquired Teva Pharmaceutical Industries Ltd.’ US store brand OTC portfolio in a move to strengthen its product pipeline. The acquisition includes 27 approved abbreviated new drug applications and 14 pending ANDAs, including nicotine replacement therapy (NRT) products, and the first-to-market store-brand rival to Abreva (docosanol 10%) cold-sore cream.
According to PLD, “this important acquisition supports the company’s focus of growing its range of products, with an emphasis on...
